HSCI Index Rebalance and Stock Connect: Early Look at Potential Changes
While the HSCI does not have assets benchmarked to it, the index review is closely watched since the index forms the basis of stocks that are a...
654 Views
A Different Angle - RemeGen Vs Akeso (Insights on Valuation)
In this article, by comparing RemeGen and Akeso's pipelines from different aspects to provide Ā referable and helpfulĀ insights about the valuation...
531 Views
Simcere (å 声å¶čÆ) IPO Trading: Mind the Sentiment Changes
We are of the view that the deal will not perform well compared to previous hot biotech deals as it is fairly valued and the sentiment is weak for...
621 Views
ECM Weekly (18 October 2020) - Lufax, Simcere, KWG Living, GDS, Jacobio
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This week...
559 Views
Simcere Pharmaceutical IPO: Valuation Insights
We think that an attractive PEG valuation and solid cornerstone support makes Simcere tempting at the proposed pricing range
566 Views